PL3027642T3 - Konstrukty czynnika różnicowania wzrostu 15 (GDF-15) - Google Patents

Konstrukty czynnika różnicowania wzrostu 15 (GDF-15)

Info

Publication number: PL3027642T3
Authority: PL; Poland
Prior art keywords: gdf; constructs; differentiation factor; growth differentiation; growth
Prior art date: 2013-07-31

Application number

PL14752711T

Other languages

English (en)

Inventor

Yumei Xiong

Yi Zhang

Jackie Z. Sheng

Agnes Eva Hamburger

Murielle Veniant-Ellison

Grant Shimamoto

Xiaoshan MIN

Zhulun Wang

Jie Tang

Gunasekaran Kannan

Marissa Mock

Kenneth Walker

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-31

Filing date

2014-07-31

Publication date

2021-01-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3027642(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-07-31 Application filed by Amgen Inc. filed Critical Amgen Inc.

2021-01-11 Publication of PL3027642T3 publication Critical patent/PL3027642T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Biophysics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL14752711T 2013-07-31 2014-07-31 Konstrukty czynnika różnicowania wzrostu 15 (GDF-15) PL3027642T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361860723P	2013-07-31	2013-07-31
PCT/US2014/049254 WO2015017710A1 (en)	2013-07-31	2014-07-31	Growth differentiation factor 15 (gdf-15) constructs
EP14752711.3A EP3027642B1 (en)	2013-07-31	2014-07-31	Growth differentiation factor 15 (gdf-15) constructs

Publications (1)

Publication Number	Publication Date
PL3027642T3 true PL3027642T3 (pl)	2021-01-11

Family

ID=51358091

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14752711T PL3027642T3 (pl)	2013-07-31	2014-07-31	Konstrukty czynnika różnicowania wzrostu 15 (GDF-15)

Country Status (36)

Country	Link
US (4)	US9862752B2 (pl)
EP (2)	EP3027642B1 (pl)
JP (4)	JP6509852B2 (pl)
KR (3)	KR20240000642A (pl)
CN (2)	CN113527512A (pl)
AP (1)	AP2016009011A0 (pl)
AR (1)	AR097181A1 (pl)
AU (1)	AU2014296107B2 (pl)
BR (1)	BR112016002213A2 (pl)
CA (1)	CA2918624C (pl)
CL (1)	CL2016000249A1 (pl)
CR (1)	CR20160097A (pl)
CY (1)	CY1123836T1 (pl)
DK (1)	DK3027642T3 (pl)
EA (2)	EA202092386A1 (pl)
ES (1)	ES2828670T3 (pl)
HK (1)	HK1225738A1 (pl)
HU (1)	HUE050630T2 (pl)
IL (1)	IL243749B (pl)
JO (1)	JO3566B1 (pl)
LT (1)	LT3027642T (pl)
MA (1)	MA38873B1 (pl)
MX (2)	MX369152B (pl)
NZ (2)	NZ717030A (pl)
PE (1)	PE20160189A1 (pl)
PH (1)	PH12016500208A1 (pl)
PL (1)	PL3027642T3 (pl)
PT (1)	PT3027642T (pl)
SG (1)	SG11201600713RA (pl)
SI (1)	SI3027642T1 (pl)
TN (1)	TN2016000035A1 (pl)
TW (1)	TWI648401B (pl)
UA (1)	UA116665C2 (pl)
UY (1)	UY35686A (pl)
WO (1)	WO2015017710A1 (pl)
ZA (1)	ZA201600523B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2832581C (en)	2011-04-08	2022-08-23	Yumei Xiong	Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
KR20140125803A (ko) *	2012-01-26	2014-10-29	암젠 인크	성장 분화 인자 15(gdf-15) 폴리펩타이드들
WO2013148117A1 (en)	2012-03-27	2013-10-03	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
KR101993714B1 (ko)	2013-01-30	2019-06-28	엔지엠 바이오파마슈티컬스, 아이엔씨.	대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
CN113527512A (zh)	2013-07-31	2021-10-22	美国安进公司	生长分化因子15(gdf-15)构建体
JP2015182969A (ja) *	2014-03-21	2015-10-22	四国化成工業株式会社	トリアゾールシラン化合物、該化合物の合成方法及びその利用
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
EP3157947A1 (en) *	2014-06-23	2017-04-26	Novartis AG	Hsa-gdf-15 fusion polypeptide and use thereof
MX2016016063A (es)	2014-06-24	2017-03-10	Novo Nordisk As	Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.
MY192917A (en)	2014-07-30	2022-09-15	Ngm Biopharmaceuticals Inc	Compositions and methods of use for treating metabolic disorders
EP3701969A1 (en)	2014-10-31	2020-09-02	NGM Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
EP3393494A1 (en)	2015-12-22	2018-10-31	Novartis Ag	Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
CN109715206B (zh)	2016-03-31	2023-11-07	恩格姆生物制药公司	结合蛋白及其使用方法
US10336812B2 (en) *	2016-05-10	2019-07-02	Janssen Biotech, Inc.	GDF15 fusion proteins and uses thereof
CA3025251A1 (en)	2016-05-24	2017-11-30	Novo Nordisk A/S	Mic-1 compounds and uses thereof
TWI710377B (zh)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Ｍｉｃ－１化合物及其用途
KR102010652B1 (ko) *	2017-08-21	2019-08-13	서울대학교병원	간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법
CN111163795A (zh)	2017-09-10	2020-05-15	诺沃挪第克公司	用于治疗肥胖症的mic-1和glp-1
TWI724392B (zh)	2018-04-06	2021-04-11	美商美國禮來大藥廠	生長分化因子15促效劑化合物及其使用方法
JOP20200258A1 (ar) *	2018-04-09	2020-10-11	Amgen Inc	البروتينات الاندماجية لعامل تمايز النمو 15
CA3106146A1 (en) *	2018-07-13	2020-01-16	Genmab A/S	Variants of cd38 antibody and uses thereof
EA202191105A1 (ru) *	2018-10-22	2021-08-03	Янссен Фармацевтика Нв	Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
MX2021012964A (es) *	2019-04-23	2021-12-10	Lg Chemical Ltd	Polipeptido de fusion que comprende region fc de inmunoglobulina y gdf15.
US20220235148A1 (en)	2019-05-30	2022-07-28	Amgen Inc.	Engineering the hinge region to drive antibody dimerization
AU2020289474A1 (en)	2019-06-07	2021-12-23	Amgen Inc.	Bispecific binding constructs
BR112022006546A2 (pt)	2019-10-07	2022-08-30	Kallyope Inc	Agonistas de gpr119
EP4065597A4 (en) *	2019-11-26	2024-01-24	Yuhan Corporation	LONG-ACTING GDF15 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION THEREFROM
JP2023505833A (ja) *	2019-12-11	2023-02-13	エルジー・ケム・リミテッド	Ｏ－グリコシル化可能なポリペプチド領域およびｇｄｆ１５を含む融合ポリペプチド
IL293994A (en)	2019-12-23	2022-08-01	Denali Therapeutics Inc	Variants of progranulin, preparations containing them and their uses
EP4085077A4 (en)	2019-12-31	2024-01-17	Beijing QL Biopharmaceutical Co., Ltd.	FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF
WO2021236617A1 (en)	2020-05-19	2021-11-25	Kallyope, Inc.	Ampk activators
EP4172162A4 (en)	2020-06-26	2024-08-07	Kallyope Inc	AMPK ACTIVATORS
EP4237438A1 (en)	2020-10-27	2023-09-06	Beijing QL Biopharmaceutical Co., Ltd.	Fusion proteins of gdf15 and use thereof
WO2022219495A1 (en)	2021-04-12	2022-10-20	Novartis Ag	2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
US20240350588A1 (en) *	2021-08-24	2024-10-24	Sunshine Lake Pharma Co., Ltd.	Gdf15 fusion proteins and use thereof
WO2023152698A1 (en)	2022-02-10	2023-08-17	Novartis Ag	2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en)	2022-02-14	2023-08-17	Ngm Biopharmaceuticals, Inc.	Gdf15 polypeptides for treating and preventing autoimmune diseases
CN115028726B (zh) *	2022-03-31	2024-01-09	浙江特瑞思药业股份有限公司	一种抗pd-1纳米抗体及其应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
EP0088046B1 (de)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipide in wässriger Phase
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en)	1983-11-01	1988-11-17	Terumo Corp	Pharmaceutical composition containing urokinase
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
US5288931A (en) *	1991-12-06	1994-02-22	Genentech, Inc.	Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5470582A (en)	1992-02-07	1995-11-28	Syntex (U.S.A.) Inc.	Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
WO1999006445A1 (en) *	1997-07-31	1999-02-11	The Johns Hopkins University School Of Medicine	Growth differentiation factor-15
SK9432001A3 (en) *	1999-01-07	2003-02-04	Lexigen Pharm Corp	Expression and export of anti-obesity proteins as Fc fusion proteins
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
GB9912350D0 (en) *	1999-05-26	1999-07-28	European Molecular Biology Lab Embl	Modified cytokine
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
ES2311560T3 (es) *	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
TWI329129B (en) *	2001-02-08	2010-08-21	Wyeth Corp	Modified and stabilized gdf propeptides and uses thereof
AU2002250293B2 (en)	2001-03-09	2007-10-11	Arnason, Barry G. Mr	Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
JP4422949B2 (ja)	2001-06-26	2010-03-03	武田薬品工業株式会社	ＴＧＦ−βスーパーファミリー産生・分泌促進剤
FI117667B (fi) *	2001-07-05	2007-01-15	Univ Zuerich	Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US7332474B2 (en)	2001-10-11	2008-02-19	Amgen Inc.	Peptides and related compounds having thrombopoietic activity
US8093357B2 (en) *	2002-03-01	2012-01-10	Xencor, Inc.	Optimized Fc variants and methods for their generation
US7101852B2 (en)	2003-05-30	2006-09-05	The Board Of Regents Of The University Of Texas System	Composition and method for treatment and prevention of restenosis
RU2322261C2 (ru) *	2003-06-02	2008-04-20	Уайт	Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2005063815A2 (en)	2003-11-12	2005-07-14	Biogen Idec Ma Inc.	Fcϝ receptor-binding polypeptide variants and methods related thereto
JP2007531513A (ja) *	2003-11-13	2007-11-08	ハンミファーム．インダストリーカンパニーリミテッド	薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
US20050249723A1 (en)	2003-12-22	2005-11-10	Xencor, Inc.	Fc polypeptides with novel Fc ligand binding sites
ES2788868T3 (es)	2004-04-13	2020-10-23	St Vincents Hospital Sydney Ltd	Método para modular el apetito
WO2005113585A2 (en) *	2004-05-20	2005-12-01	Acceleron Pharma Inc.	Modified tgf-beta superfamily polypeptides
US7670595B2 (en) *	2004-06-28	2010-03-02	Merck Patent Gmbh	Fc-interferon-beta fusion proteins
US20060034831A1 (en) *	2004-08-12	2006-02-16	Wyeth	Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
DK1931709T3 (en)	2005-10-03	2017-03-13	Xencor Inc	FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP2009515520A (ja) *	2005-11-10	2009-04-16	レセプターバイオロジックス，インコーポレイテッド	肝細胞成長因子イントロン融合蛋白
CN1974601A (zh) *	2005-11-28	2007-06-06	上海新生源医药研究有限公司	一种新型Fc融合蛋白及其生产方法
EP2057191A1 (en) *	2006-08-18	2009-05-13	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2008286706B2 (en)	2007-08-16	2014-03-06	Garvan Institute Of Medical Research	Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
DK2235064T3 (en)	2008-01-07	2016-01-11	Amgen Inc	A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
JP2011523051A (ja)	2008-05-20	2011-08-04	エフ．ホフマン−ラロシュアーゲー	１型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
BRPI0916904A2 (pt)	2008-08-04	2016-10-11	Fiveprime Therapeutics Inc	polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
CN102203619B (zh)	2008-10-31	2015-12-16	圣文森特医院悉尼有限公司	慢性肾病中的预测方法
EP2504360B1 (en)	2009-11-23	2018-08-15	Amgen Inc.	Monomeric antibody fc
WO2011064758A2 (en) *	2009-11-30	2011-06-03	Pfizer Limited	Fusion protein
MX2012006397A (es) *	2009-12-02	2012-11-30	Amgen Inc	PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
US8362210B2 (en)	2010-01-19	2013-01-29	Xencor, Inc.	Antibody variants with enhanced complement activity
CA2800971A1 (en)	2010-07-12	2012-01-19	Pfizer Limited	Chemical compounds
EP2593433B1 (en)	2010-07-12	2014-11-26	Pfizer Limited	N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
EP2593428B1 (en)	2010-07-12	2014-11-19	Pfizer Limited	N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
ES2534921T3 (es)	2010-08-26	2015-04-30	F. Hoffmann-La Roche Ag	Uso de biomarcadores en la evaluación de la transición temprana de la hipertensión arterial a la insuficiencia cardíaca
EP2439535A1 (en)	2010-10-07	2012-04-11	F. Hoffmann-La Roche AG	Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus
US9562109B2 (en) *	2010-11-05	2017-02-07	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the Fc domain
AU2012229048B2 (en)	2011-03-16	2016-01-21	Amgen Inc	Fc variants
CA2832581C (en) *	2011-04-08	2022-08-23	Yumei Xiong	Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
LT2697257T (lt) *	2011-04-13	2016-12-27	Bristol-Myers Squibb Company	Su fc sulieti baltymai, apimantys naujus linkerius ir išsidėstimus
EA201892619A1 (ru) *	2011-04-29	2019-04-30	Роше Гликарт Аг	Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PT2794905T (pt) *	2011-12-20	2020-06-30	Medimmune Llc	Polipéptidos modificados para estrutura de anticorpos bispecíficos
KR20140125803A (ko)	2012-01-26	2014-10-29	암젠 인크	성장 분화 인자 15(gdf-15) 폴리펩타이드들
WO2013148117A1 (en) *	2012-03-27	2013-10-03	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
PL2838918T3 (pl) *	2012-04-20	2019-11-29	Merus Nv	Sposoby i środki do wytwarzania heterodimerycznych cząsteczek podobnych do ig
JP6758832B2 (ja)	2012-12-21	2020-09-30	アベオファーマシューティカルズ，インコーポレイテッド	抗ｇｄｆ１５抗体
KR101993714B1 (ko) *	2013-01-30	2019-06-28	엔지엠 바이오파마슈티컬스, 아이엔씨.	대사 장애를 치료하는데 이용하기 위한 조성물과 방법
CN113527512A (zh) *	2013-07-31	2021-10-22	美国安进公司	生长分化因子15(gdf-15)构建体
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
EP3157947A1 (en) *	2014-06-23	2017-04-26	Novartis AG	Hsa-gdf-15 fusion polypeptide and use thereof
CN106573955B (zh)	2014-06-23	2021-02-26	诺华股份有限公司	位点特异性蛋白质修饰
MX2016016063A (es)	2014-06-24	2017-03-10	Novo Nordisk As	Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas.
EP3393494A1 (en)	2015-12-22	2018-10-31	Novartis Ag	Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en)	2016-05-10	2019-07-02	Janssen Biotech, Inc.	GDF15 fusion proteins and uses thereof
CA3025251A1 (en)	2016-05-24	2017-11-30	Novo Nordisk A/S	Mic-1 compounds and uses thereof
TWI724392B (zh)	2018-04-06	2021-04-11	美商美國禮來大藥廠	生長分化因子15促效劑化合物及其使用方法

2014
- 2014-07-31 CN CN202110685579.XA patent/CN113527512A/zh active Pending
- 2014-07-31 CA CA2918624A patent/CA2918624C/en active Active
- 2014-07-31 CN CN201480043522.8A patent/CN105980400B/zh active Active
- 2014-07-31 UY UY0001035686A patent/UY35686A/es active IP Right Grant
- 2014-07-31 NZ NZ717030A patent/NZ717030A/en unknown
- 2014-07-31 MX MX2016001164A patent/MX369152B/es active IP Right Grant
- 2014-07-31 KR KR1020237043685A patent/KR20240000642A/ko active Search and Examination
- 2014-07-31 LT LTEP14752711.3T patent/LT3027642T/lt unknown
- 2014-07-31 TW TW103126283A patent/TWI648401B/zh active
- 2014-07-31 DK DK14752711.3T patent/DK3027642T3/da active
- 2014-07-31 UA UAA201601817A patent/UA116665C2/uk unknown
- 2014-07-31 PT PT147527113T patent/PT3027642T/pt unknown
- 2014-07-31 SG SG11201600713RA patent/SG11201600713RA/en unknown
- 2014-07-31 SI SI201431664T patent/SI3027642T1/sl unknown
- 2014-07-31 KR KR1020227008673A patent/KR102616674B1/ko active IP Right Grant
- 2014-07-31 HU HUE14752711A patent/HUE050630T2/hu unknown
- 2014-07-31 PE PE2016000103A patent/PE20160189A1/es unknown
- 2014-07-31 EA EA202092386A patent/EA202092386A1/ru unknown
- 2014-07-31 KR KR1020167005421A patent/KR102376451B1/ko active IP Right Grant
- 2014-07-31 PL PL14752711T patent/PL3027642T3/pl unknown
- 2014-07-31 TN TN2016000035A patent/TN2016000035A1/en unknown
- 2014-07-31 BR BR112016002213A patent/BR112016002213A2/pt not_active Application Discontinuation
- 2014-07-31 NZ NZ754961A patent/NZ754961A/en unknown
- 2014-07-31 AU AU2014296107A patent/AU2014296107B2/en active Active
- 2014-07-31 AR ARP140102882A patent/AR097181A1/es unknown
- 2014-07-31 WO PCT/US2014/049254 patent/WO2015017710A1/en active Application Filing
- 2014-07-31 ES ES14752711T patent/ES2828670T3/es active Active
- 2014-07-31 JP JP2016531912A patent/JP6509852B2/ja active Active
- 2014-07-31 MA MA38873A patent/MA38873B1/fr unknown
- 2014-07-31 EP EP14752711.3A patent/EP3027642B1/en active Active
- 2014-07-31 AP AP2016009011A patent/AP2016009011A0/xx unknown
- 2014-07-31 EP EP20189041.5A patent/EP3763734A1/en active Pending
- 2014-07-31 EA EA201690297A patent/EA037355B1/ru not_active IP Right Cessation
- 2014-07-31 US US14/908,459 patent/US9862752B2/en active Active
- 2014-08-03 JO JOP/2014/0240A patent/JO3566B1/ar active
2016
- 2016-01-24 IL IL243749A patent/IL243749B/en active IP Right Grant
- 2016-01-25 ZA ZA2016/00523A patent/ZA201600523B/en unknown
- 2016-01-27 MX MX2019012848A patent/MX2019012848A/es unknown
- 2016-01-29 PH PH12016500208A patent/PH12016500208A1/en unknown
- 2016-01-29 CL CL2016000249A patent/CL2016000249A1/es unknown
- 2016-02-29 CR CR20160097A patent/CR20160097A/es unknown
- 2016-12-05 HK HK16113820A patent/HK1225738A1/zh unknown
2017
- 2017-11-29 US US15/826,442 patent/US10894814B2/en active Active
2019
- 2019-04-02 JP JP2019070364A patent/JP6877478B2/ja active Active
2020
- 2020-10-09 CY CY20201100954T patent/CY1123836T1/el unknown
- 2020-11-11 US US17/094,968 patent/US20210079051A1/en not_active Abandoned
2021
- 2021-04-26 JP JP2021073836A patent/JP2021113219A/ja active Pending
2023
- 2023-06-16 JP JP2023099006A patent/JP2023116723A/ja active Pending
2024
- 2024-04-18 US US18/639,202 patent/US20240368236A1/en active Pending

Also Published As

Publication number	Publication date
ES2828670T3 (es)	2021-05-27
TW201602345A (zh)	2016-01-16
EP3763734A1 (en)	2021-01-13
EA037355B1 (ru)	2021-03-17
NZ717030A (en)	2022-04-29
KR20220038829A (ko)	2022-03-29
LT3027642T (lt)	2020-10-12
TWI648401B (zh)	2019-01-21
UY35686A (es)	2015-01-30
NZ754961A (en)	2022-04-29
JP2019178132A (ja)	2019-10-17
US10894814B2 (en)	2021-01-19
JP2023116723A (ja)	2023-08-22
PH12016500208B1 (en)	2016-04-25
KR102616674B1 (ko)	2023-12-29
US9862752B2 (en)	2018-01-09
CN105980400A (zh)	2016-09-28
SG11201600713RA (en)	2016-02-26
US20210079051A1 (en)	2021-03-18
CN113527512A (zh)	2021-10-22
MA38873A1 (fr)	2017-09-29
US20160168213A1 (en)	2016-06-16
TN2016000035A1 (en)	2017-07-05
JO3566B1 (ar)	2020-07-05
AP2016009011A0 (en)	2016-01-31
CA2918624A1 (en)	2015-02-05
BR112016002213A2 (pt)	2017-08-29
SI3027642T1 (sl)	2020-11-30
JP6509852B2 (ja)	2019-05-08
KR20160038896A (ko)	2016-04-07
DK3027642T3 (da)	2020-11-02
HUE050630T2 (hu)	2020-12-28
US20180079790A1 (en)	2018-03-22
KR20240000642A (ko)	2024-01-02
AR097181A1 (es)	2016-02-24
CL2016000249A1 (es)	2016-07-22
MX2016001164A (es)	2016-07-26
ZA201600523B (en)	2024-10-30
WO2015017710A1 (en)	2015-02-05
PT3027642T (pt)	2020-10-30
AU2014296107B2 (en)	2018-07-26
MX369152B (es)	2019-10-30
EA202092386A1 (ru)	2021-04-30
EP3027642A1 (en)	2016-06-08
CN105980400B (zh)	2021-05-07
KR102376451B1 (ko)	2022-03-23
CR20160097A (es)	2016-07-29
US20240368236A1 (en)	2024-11-07
PE20160189A1 (es)	2016-05-06
HK1225738A1 (zh)	2017-09-15
CY1123836T1 (el)	2022-03-24
IL243749B (en)	2018-06-28
EA201690297A1 (ru)	2016-06-30
JP2021113219A (ja)	2021-08-05
MX2019012848A (es)	2019-11-28
IL243749A0 (en)	2016-04-21
JP6877478B2 (ja)	2021-05-26
EP3027642B1 (en)	2020-08-19
JP2016532690A (ja)	2016-10-20
MA38873B1 (fr)	2018-11-30
UA116665C2 (uk)	2018-04-25
PH12016500208A1 (en)	2016-04-25
AU2014296107A1 (en)	2016-02-04
CA2918624C (en)	2024-02-13

Publication	Publication Date	Title
HK1225738A1 (zh)	2017-09-15	生長分化因子15(gdf-15)構建體
HRP20190502T1 (hr)	2019-05-03	Afukozilirana anti-fgfr2iiib protutijela
IL233725A0 (en)	2014-09-30	Growth and differentiation factor 15 (gdf-15) polypeptides
HK1203357A1 (en)	2015-10-30	Fibroblast growth factor 21 proteins 21
GB2530923B (en)	2020-05-20	Smart shaker room
GB201302597D0 (en)	2013-04-03	Novel Synthetic Proteins
HK1219961A1 (zh)	2017-04-21	人抗α型干擾素抗體
SI3016977T1 (sl)	2020-03-31	Humana protitelesa proti IL-32
EP3511466C0 (en)	2023-06-07	LEMINSCATE SHAPED WINDINGS
GB201312513D0 (en)	2013-08-28	2 4 1 Technology
GB201304642D0 (en)	2013-05-01	02 Planter
GB201322568D0 (en)	2014-02-05	Taggstar 1
GB201308820D0 (en)	2013-07-03	Part 3 under
AU350589S (en)	2013-09-04	Joiner (2)
AU350588S (en)	2013-09-04	Joiner (1)
GB201310407D0 (en)	2013-08-07	Plantladders 3
GB201310285D0 (en)	2013-07-24	Twist-Away 270